First Time Loading...

Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 6.26 USD 1.62% Market Closed
Updated: May 5, 2024

Travere Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Travere Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Travere Therapeutics Inc
NASDAQ:TVTX
Operating Income
-$376.7m
CAGR 3-Years
-68%
CAGR 5-Years
-36%
CAGR 10-Years
-31%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Travere Therapeutics Inc's Operating Income?
Operating Income
-376.7m USD

Based on the financial report for Dec 31, 2023, Travere Therapeutics Inc's Operating Income amounts to -376.7m USD.

What is Travere Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-31%

Over the last year, the Operating Income growth was -41%. The average annual Operating Income growth rates for Travere Therapeutics Inc have been -68% over the past three years , -36% over the past five years , and -31% over the past ten years .